What is Tenaya Therapeutics Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tenaya Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.42.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tenaya Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Tenaya Therapeutics's Cash-to-Debt or its related term are showing as below:
TNYA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 8.42 Med: 16.01 Max: No Debt
Current: 8.42
During the past 5 years, Tenaya Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 8.42. And the median was 16.01.
Tenaya Therapeutics Cash-to-Debt Historical Data
The historical data trend for Tenaya Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Tenaya Therapeutics Cash-to-Debt Chart
|
Tenaya Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
No Debt |
No Debt |
16.01 |
12.35 |
8.42 |
|
Tenaya Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
12.35 |
10.47 |
10.11 |
10.11 |
8.42 |
Competitive Comparison of Tenaya Therapeutics's Cash-to-Debt
For the Biotechnology subindustry, Tenaya Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's Cash-to-Debt falls into.
Tenaya Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Tenaya Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Tenaya Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics (Tenaya Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Executives
| Timothy Hoey |
officer: Chief Scientific Officer |
C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080 |
| Leone D Patterson |
officer: Chief Fin and Bus. Officer |
|
| Whittemore Tingley |
officer: Chief Medical Officer |
C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
| Faraz Ali |
director, officer: Chief Executive Officer |
C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080 |
| David V Goeddel |
director, 10 percent owner |
C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Column Group Iii Gp, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Amy L. Burroughs |
director |
TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
| Column Group Iii, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Column Group Opportunity Iii Gp, Lp |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
| Tcg Opportunity Iii Gp, Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
| Column Group Opportunity Iii, Lp |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
| Deepak Srivastava |
director |
C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
| Column Group Iii-a, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Eli Casdin |
director |
1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
| Casdin Capital, Llc |
director |
1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Tenaya Therapeutics (Tenaya Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNYA has been successfully added to your